Patents by Inventor Melissa Vasbinder

Melissa Vasbinder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210171541
    Abstract: Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.
    Type: Application
    Filed: July 17, 2020
    Publication date: June 10, 2021
    Inventors: Bernard Barlaam, Christopher De Savi, Janet Hawkins, Alexander Hird, Michelle Lamb, Kurt Pike, Melissa Vasbinder
  • Publication number: 20210078981
    Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 28, 2020
    Publication date: March 18, 2021
    Applicant: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Annika Birgitta Margareta ASTRAND, Neil Patrick GRIMSTER, Sameer KAWATKAR, Jason Grant KETTLE, Magnus K. NILSSON, Linette RUSTON, Qibin SU, Melissa VASBINDER, Jon James WINTER-HOLT, Richard Donald WOESSNER, Claudio Edmundo CHUAQUI, James MCCABE
  • Patent number: 10717746
    Abstract: Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: July 21, 2020
    Assignee: ASTRAZENECA AB
    Inventors: Bernard Barlaam, Christopher De Savi, Janet Hawkins, Alexander Hird, Michelle Lamb, Kurt Pike, Melissa Vasbinder
  • Patent number: 10654835
    Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: May 19, 2020
    Assignee: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Annika Birgitta Margareta Astrand, Neil Patrick Grimster, Sameer Kawatkar, Jason Grant Kettle, Magnus K. Nilsson, Linette Ruston, Qibin Su, Melissa Vasbinder, Jon James Winter-Holt, Richard Donald Woessner, Claudio Edmundo Chuaqui, James McCabe
  • Publication number: 20190092760
    Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 20, 2018
    Publication date: March 28, 2019
    Applicant: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Annika ASTRAND, Neil GRIMSTER, Sameer KAWATKAR, Jason Grant KETTLE, Magnus K NILSSON, Linette RUSTON, Qibin SU, Melissa VASBINDER, Jon James WINTER-HOLT, Richard Donald WOESSNER, Claudio Edmundo CHUAQUI, James MCCABE
  • Patent number: 10167276
    Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: January 1, 2019
    Assignee: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Inventors: Annika Astrand, Neil Grimster, Sameer Kawatkar, Jason Grant Kettle, Magnus K Nilsson, Linette Ruston, Qibin Su, Melissa Vasbinder, Jon James Winter-Holt, Richard Donald Woessner, Claudio Edmundo Chuaqui, James McCabe
  • Publication number: 20180093998
    Abstract: Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.
    Type: Application
    Filed: December 6, 2017
    Publication date: April 5, 2018
    Inventors: Bernard Barlaam, Christopher De Savi, Janet Hawkins, Alexander Hird, Michelle Lamb, Kurt Pike, Melissa Vasbinder
  • Patent number: 9845331
    Abstract: Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: December 19, 2017
    Assignee: AstraZeneca AB
    Inventors: Bernard Barlaam, Christopher De Savi, Janet Hawkins, Alexander Hird, Michelle Lamb, Kurt Pike, Melissa Vasbinder
  • Publication number: 20170320857
    Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 22, 2017
    Publication date: November 9, 2017
    Applicant: AstraZeneca AB
    Inventors: Annika ASTRAND, Neil GRIMSTER, Sameer KAWATKAR, Jason Grant KETTLE, Magnus K NILSSON, Linette RUSTON, Qibin SU, Melissa VASBINDER, Jon James WINTER-HOLT, Richard Donald WOESSNER, Claudio Edmundo CHUAQUI, James MCCABE
  • Patent number: 9714236
    Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: July 25, 2017
    Assignee: ASTRAZENECA AB
    Inventors: Neil Grimster, Sameer Kawatkar, Jason Grant Kettle, Qibin Su, Melissa Vasbinder, Claudio Edmundo Chuaqui
  • Publication number: 20170088543
    Abstract: Disclosed are compounds of formula (I), pharmaceutical compositions comprising such compounds and methods/uses of using the same, for example, for treating a JAK-related disorder, such as cancer, cancer cachexia or an immune disorder: wherein R1 is methyl or ethyl; R2 is selected from methyl, ethyl, methoxy and ethoxy; R3 is selected from hydrogen, chlorine, fluorine, bromine and methyl; R4 is selected from methyl, ethyl and —CH2OCH3; R5 and R6 are each individually methyl or hydrogen; and R7 is selected from methyl, ethyl, —(CH2)2OH and —(CH2)2OCH3, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 22, 2016
    Publication date: March 30, 2017
    Applicant: AstraZeneca AB
    Inventors: Annika ASTRAND, Neil GRIMSTER, Sameer KAWATKAR, Jason Grant KETTLE, Magnus K. NILSSON, Linette RUSTON, Qibin SU, Melissa VASBINDER, Jon James WINTER-HOLT, Richard Donald WOESSNER, Claudio Edmundo CHUAQUI, Dedong WU, Wenzhan YANG, Tudor GRECU, James MCCABE
  • Publication number: 20160376287
    Abstract: Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.
    Type: Application
    Filed: June 27, 2016
    Publication date: December 29, 2016
    Applicant: AstraZeneca AB
    Inventors: Bernard Barlaam, Christopher De Savi, Janet Hawkins, Alexander Hird, Michelle Lamb, Kurt Pike, Melissa Vasbinder
  • Publication number: 20100216791
    Abstract: The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B-Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.
    Type: Application
    Filed: August 15, 2007
    Publication date: August 26, 2010
    Applicant: ASTRAZENECA
    Inventors: Brian Aquila, Donald J. Cook, Craig Johnstone, Stephen Lee, Paul Lyne, David Alan Rudge, Melissa Vasbinder, Haixia Wang
  • Publication number: 20090275570
    Abstract: The invention relates to novel compounds of Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds possess CHK1 kinase inhibitory activity, PDK1 inhibitory activity and Pak kinase inhibitory activity and are accordingly useful in the treatment and/or prophylaxis of cancer.
    Type: Application
    Filed: April 5, 2006
    Publication date: November 5, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Kevin Daly, Nicola Heron, Alexander Hird, Stephanos Ioannidis, James Janetka, Paul Lyne, Jaime Scott, Dorin Toader, Melissa Vasbinder, Dingwei Yu, Yan Yu